X4 PHARMACEUTICALS, INC Operating Income
X4 PHARMACEUTICALS, INC (XFOR) reported Operating Income of -$16.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC operating income (loss) for the quarter ending 2026-06-30 was -$16.39M.
- X4 PHARMACEUTICALS, INC operating income (loss) for the quarter ending 2026-03-31 was -$20.31M.
- X4 PHARMACEUTICALS, INC operating income (loss) for the quarter ending 2025-12-31 was -$23.70M.
- X4 PHARMACEUTICALS, INC operating income (loss) for the quarter ending 2025-09-30 was -$27.51M.
- X4 PHARMACEUTICALS, INC operating income (loss) for fiscal 2025 was -$86.88M.
- X4 PHARMACEUTICALS, INC operating income (loss) for fiscal 2024 was -$36.40M.
- X4 PHARMACEUTICALS, INC operating income (loss) for fiscal 2023 was -$107.52M.
- X4 PHARMACEUTICALS, INC operating income (loss) for fiscal 2022 was -$87.57M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$16.39M 10-Q · filed 2026-08-06 | -$36.70M 10-Q · filed 2026-08-06 | -$60.40M derived: sum of 3 quarters · filed 2026-08-06 | -$87.91M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$20.31M 10-Q · filed 2026-05-06 | -$44.01M derived: sum of 2 quarters · filed 2026-05-06 | -$71.51M derived: sum of 3 quarters · filed 2026-05-06 | -$97.75M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$23.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$51.21M derived: sum of 2 quarters · filed 2026-03-17 | -$77.44M derived: sum of 3 quarters · filed 2026-08-06 | -$86.88M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | -$27.51M 10-Q · filed 2025-11-05 | -$53.74M derived: sum of 2 quarters · filed 2026-08-06 | -$63.18M 10-Q · filed 2025-11-05 | -$98.90M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$26.23M 10-Q · filed 2026-08-06 | -$35.67M 10-Q · filed 2026-08-06 | -$71.39M derived: sum of 3 quarters · filed 2026-08-06 | -$105.89M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$9.44M 10-Q · filed 2026-05-06 | -$45.16M derived: sum of 2 quarters · filed 2026-05-06 | -$79.66M derived: sum of 3 quarters · filed 2026-05-06 | -$8.55M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$35.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$70.22M derived: sum of 2 quarters · filed 2026-03-17 | $888.00K derived: sum of 3 quarters · filed 2026-03-17 | -$36.40M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | -$34.50M 10-Q · filed 2025-11-05 | $36.60M derived: sum of 2 quarters · filed 2025-11-05 | -$686.00K 10-Q · filed 2025-11-05 | -$25.89M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2024-06-30 | $71.10M 10-Q · filed 2025-08-08 | $33.81M 10-Q · filed 2025-08-08 | $8.62M derived: sum of 3 quarters · filed 2026-03-17 | -$18.60M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2024-03-31 | -$37.29M 10-Q · filed 2025-05-01 | -$62.49M derived: sum of 2 quarters · filed 2026-03-17 | -$89.70M derived: sum of 3 quarters · filed 2026-03-17 | -$115.51M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2023-12-31 | -$25.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$52.41M derived: sum of 2 quarters · filed 2026-03-17 | -$78.22M derived: sum of 3 quarters · filed 2026-03-17 | -$107.52M 10-K · filed 2026-03-17 | ||||
| 2023-09-30 | -$27.21M 10-Q · filed 2024-11-13 | -$53.02M derived: sum of 2 quarters · filed 2024-11-13 | -$82.32M 10-Q · filed 2024-11-13 | -$107.90M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-06-30 | -$25.80M 10-Q · filed 2024-08-08 | -$55.11M 10-Q · filed 2024-08-08 | -$80.69M derived: sum of 3 quarters · filed 2025-03-26 | -$100.84M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-03-31 | -$29.30M 10-Q · filed 2024-05-07 | -$54.88M derived: sum of 2 quarters · filed 2025-03-26 | -$75.03M derived: sum of 3 quarters · filed 2025-03-26 | -$95.61M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2022-12-31 | -$25.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$45.73M derived: sum of 2 quarters · filed 2025-03-26 | -$66.30M derived: sum of 3 quarters · filed 2025-03-26 | -$87.57M 10-K · filed 2025-03-26 | ||||
| 2022-09-30 | -$20.15M 10-Q · filed 2023-11-09 | -$40.72M derived: sum of 2 quarters · filed 2023-11-09 | -$61.99M 10-Q · filed 2023-11-09 | -$91.05M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-06-30 | -$20.57M 10-Q · filed 2023-08-10 | -$41.84M 10-Q · filed 2023-08-10 | -$70.89M derived: sum of 3 quarters · filed 2024-03-21 | -$90.01M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | -$21.27M 10-Q · filed 2023-05-04 | -$50.32M derived: sum of 2 quarters · filed 2024-03-21 | -$69.44M derived: sum of 3 quarters · filed 2024-03-21 | -$88.44M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2021-12-31 | -$29.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$48.17M derived: sum of 2 quarters · filed 2024-03-21 | -$67.17M derived: sum of 3 quarters · filed 2024-03-21 | -$85.11M 10-K · filed 2024-03-21 | ||||
| 2021-09-30 | -$19.12M 10-Q · filed 2022-11-03 | -$38.12M derived: sum of 2 quarters · filed 2022-11-03 | -$56.05M 10-Q · filed 2022-11-03 | -$73.71M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-06-30 | -$19.00M 10-Q · filed 2022-08-04 | -$36.93M 10-Q · filed 2022-08-04 | -$54.59M derived: sum of 3 quarters · filed 2023-03-21 | -$71.57M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-03-31 | -$17.94M 10-Q · filed 2022-05-12 | -$35.59M derived: sum of 2 quarters · filed 2023-03-21 | -$52.57M derived: sum of 3 quarters · filed 2023-03-21 | -$67.23M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2020-12-31 | -$17.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$34.63M derived: sum of 2 quarters · filed 2023-03-21 | -$49.29M derived: sum of 3 quarters · filed 2023-03-21 | -$59.87M 10-K · filed 2023-03-21 | ||||
| 2020-09-30 | -$16.98M 10-Q · filed 2021-11-04 | -$31.64M derived: sum of 2 quarters · filed 2021-11-04 | -$42.22M 10-Q · filed 2021-11-04 | -$53.09M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | -$14.66M 10-Q · filed 2021-08-03 | -$25.24M 10-Q · filed 2021-08-03 | -$36.11M derived: sum of 3 quarters · filed 2022-03-17 | -$53.09M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | -$10.58M 10-Q · filed 2021-05-06 | -$21.46M derived: sum of 2 quarters · filed 2022-03-17 | -$38.43M derived: sum of 3 quarters · filed 2022-03-17 | -$51.85M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | -$10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$27.85M derived: sum of 2 quarters · filed 2022-03-17 | -$41.27M derived: sum of 3 quarters · filed 2022-03-17 | -$51.70M 10-K · filed 2022-03-17 | ||||
| 2019-09-30 | -$16.98M 10-Q · filed 2020-11-05 | -$30.39M derived: sum of 2 quarters · filed 2020-11-05 | -$40.83M 10-Q · filed 2020-11-05 | -$48.88M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-06-30 | -$13.41M 10-Q · filed 2020-08-04 | -$23.85M 10-Q · filed 2020-08-04 | -$31.91M derived: sum of 3 quarters · filed 2021-03-19 | -$40.45M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-03-31 | -$10.44M 10-Q · filed 2020-05-07 | -$18.49M derived: sum of 2 quarters · filed 2021-03-19 | -$27.04M derived: sum of 3 quarters · filed 2021-03-19 | -$33.41M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2018-12-31 | -$8.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | -$16.60M derived: sum of 2 quarters · filed 2021-03-19 | -$22.98M derived: sum of 3 quarters · filed 2021-03-19 | -$29.09M 10-K · filed 2021-03-19 | -$45.88M 10-K · filed 2019-03-11 | |||
| 2018-09-30 | -$8.54M 10-Q · filed 2019-11-07 | -$12.85M 10-Q · filed 2018-11-09 | -$14.92M derived: sum of 2 quarters · filed 2019-11-07 | -$21.03M 10-Q · filed 2019-11-07 | -$36.41M 10-Q · filed 2018-11-09 | -$18.75M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | -$6.38M 10-Q · filed 2019-08-07 | -$12.62M 10-Q · filed 2018-08-13 | -$12.49M 10-Q · filed 2019-08-07 | -$23.57M 10-Q · filed 2018-08-13 | -$10.21M derived: sum of 3 quarters · filed 2020-03-12 | -$23.26M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | -$6.11M 10-Q · filed 2019-05-15 | -$10.95M 10-Q · filed 2018-05-10 | -$3.83M derived: sum of 2 quarters · filed 2020-03-12 | -$16.89M derived: sum of 3 quarters · filed 2020-03-12 | -$22.53M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$10.78M derived: sum of 2 quarters · filed 2020-03-12 | -$16.42M derived: sum of 3 quarters · filed 2020-03-12 | -$22.25M 10-K · filed 2020-03-12 | -$36.13M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | -$13.06M 10-Q · filed 2018-11-09 | -$18.70M derived: sum of 2 quarters · filed 2018-11-09 | -$24.53M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | -$5.64M 10-Q · filed 2018-08-13 | -$11.47M 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | -$5.83M 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | -$24.35M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |